Vaccine News and Research

Latest Vaccine News and Research

New genotype may be responsible for sharp rise in whooping cough

Australia's prolonged whooping cough epidemic has entered a disturbing new phase, with a study showing a new strain or genotype may be responsible for the sharp rise in the number of cases.

22 Mar 2012

Whooping cough outbreak despite vaccination

...

21 Mar 2012

Top scientific experts publish new TB vaccine Blueprint

21 Mar 2012

Transforming biomedical research to develop TB vaccines

In the past decade, scientists have made significant progress building the critical knowledge and infrastructure needed to identify and develop novel tuberculosis (TB) vaccine candidates and move the most promising ones into human clinical trials. The results of those trials, coupled with advances from other TB studies, have paved the way for the next 10 years of research on TB vaccines, a critical component of TB control efforts, note scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

21 Mar 2012

Closer to effective screening for TB

An Australian scientist will bring effective screening for tuberculosis a step closer with his latest study in Vietnam- where he now lives and works.

21 Mar 2012

IDSA releases new rhinosinusitis guidelines

The vast majority of sinus infections are caused by viruses and should not be treated with antibiotics, suggest new guidelines released by the Infectious Diseases Society of America.

21 Mar 2012

GeoVax enters into definitive agreements to sell Series A convertible preferred stock

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common stock with an exercise price of $1.00 per share and a term of five years.

21 Mar 2012

New vaccine strategy to advance solutions for tuberculosis

Against a backdrop of growing concern about the impact of tuberculosis on children, top scientific experts today published a global plan of action for developing the vaccines that are seen as critical to eliminating the disease. Published today in a special issue of the journal, Tuberculosis , the strategic blueprint for the TB vaccine field, represents consensus reached by the TB vaccine community.

20 Mar 2012

Sharp rise recorded in cases of new strain of whooping cough: New genotype may be evading vaccine’s protective effects

Australia’s prolonged whooping cough epidemic has entered a disturbing new phase, with a study showing a new strain or genotype may be responsible for the sharp rise in the number of cases.

20 Mar 2012

Chemists produce first high resolution structure of HCV viral RNA-inhibitor complex

Chemists at the University of California, San Diego have produced the first high resolution structure of a molecule that when attached to the genetic material of the hepatitis C virus prevents it from reproducing.

20 Mar 2012

Mayo Clinic researchers train mouse immune systems to eradicate skin cancer from within

Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors.

20 Mar 2012

Two Cedars-Sinai physicians to receive ACC Distinguished Scientist Award

Two physicians from the Cedars-Sinai Heart Institute will receive the American College of Cardiology's highest honors for scientific research and clinical care during the organization's upcoming annual scientific meeting in Chicago.

20 Mar 2012

PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine

PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.

19 Mar 2012

Pfizer supports First World Congress on Healthy and Active Ageing

As an official partner of the First World Congress on Healthy Ageing, Pfizer reaffirms the company's commitment to promote healthy and active ageing at all stages of life as a basis for enhanced productivity in the Asia Pacific. Pfizer will lead a luncheon symposium today focused on the relationship between health and economic sustainability and the resulting challenges and opportunities of shifting demographics across the region.

19 Mar 2012

Gates Foundation grants biotech firm Aeras $220 million over 5 years to develop TB vaccines

The Bill & Melinda Gates Foundation is "to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis [TB], a company statement said Thursday," Agence France-Presse reports (3/15).

17 Mar 2012

Extremely contagious RSV virus can lead to serious illness in young children

Respiratory Syncytial Virus (RSV) is a common virus that infects the lungs and breathing passage ways. Though it may only produce minor cold symptoms in adults, it can lead to serious illness in young children and those with compromised immune systems.

17 Mar 2012

Collaborative research discovers genetic marker that identifies pigs with reduced susceptibility to PRRS

A collaborative discovery involving Kansas State University researchers may improve animal health and save the U.S. pork industry millions of dollars each year.

16 Mar 2012

Study reveals why development of HIV treatments has been difficult

A new research report appearing in the March 2012 issue of the journal Genetics shows why the development of a cure and new treatments for HIV has been so difficult. In the report, an Australian scientist explains how he used computer simulations to discover that a population starting from a single human immunodeficiency virus can evolve fast enough to escape immune defenses.

16 Mar 2012

Third International Symposium on Thymosins in Health and Disease to take place on GW campus

The George Washington University is host to the world's leaders in the area of research that focuses on Thymosins- small proteins present in many animal tissues that have diverse biological activities- Two in particular, thymosins α1 and β4, have potentially important uses in medicine, and research has already progressed from the laboratory to the clinic.

16 Mar 2012

Allergy-free egg in the making

Researchers at CSIRO and experts at Geelong's Deakin University have found a way to “switch off” four egg allergens. These modified eggs could produce chickens that lay hypoallergenic eggs but the genes and DNA of the chicken would remain unaltered.

15 Mar 2012